yellow title background



HCM Strategists is known nationally for its leadership in the areas of health, patient advocacy and medical research policy development and analysis. The experts on our team have deep content knowledge in the areas of clinical research, regulatory and reimbursement matters and care issues. Our understanding of the major patient organizations—how they operate, how they are structured, and how they set priorities—helps clients advance public policies by utilizing the power of the patient voice.

HCM’s record of success is based on our ability to leverage our comprehensive network, forge creative alliances with non-traditional partners, define clear goals and motivate communities. Our seasoned professionals are not only equipped to advise, but often provide leadership and strategic vision to these efforts on behalf of our clients. We search out innovation and put our clients at the forefront of new ways to address industry problems. Our experts support our counsel with research, data analysis and reports on important trends in health care and medical research to create everything from landscape analyses to detailed strategic roadmaps.

From nonprofits to healthcare providers to the pharmaceutical industry, we develop and implement communications, government relations, and advocacy strategies for a broad array of clients. We brief leaders in federal and state health care legislation, regulations and policies that impact health care facilities, providers, patients and communities.

Additionally, team members work collaboratively with our clients to:

  • Provide support and strategic guidance to help form policy priorities for the diabetes, paralysis, disability and patient communities
  • Design and implement targeted grassroots and grasstops advocacy campaigns
  • Design and lead advocate trainings
  • Bring patient organizations together and lead coalition efforts focused on legislative and regulatory priorities
  • Engage directly with FDA, NIH and CDC on issues that impact patient populations
  • Identify opportunities to directly engage on policy issues in a strategic, coordinated fashion
  • Secure additional federal funding for clinical research
  • Clarify regulatory pathways and accelerate the approval of new technologies and treatments
<?php echo $alt; ?>
callout link to /HCM_Diabetes_Digital_Brochure_Ind.pdf